# Cannabis and COVID-19

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/d79-cannabis-and-covid-19-png/
> **Published:** 2026-09-04T23:05:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:04-04:00
> **Clinical Summary:** A diagram-led look at how cannabinoids might interact with the stages and symptoms of COVID-19 infection, and where the evidence stands.

---

[← Back to Medical Applications Summary Hub](https://cedclinic.com/topic-medical-applications/)

Table of Contents

- [🔍 CED Perspective Lens: Cannabis and COVID-19](#_CED_Perspective_Lens_Cannabis_and_COVID-19)
- [Understanding the Potential Role of Cannabinoids in COVID-19 Progression and Treatment](#Understanding_the_Potential_Role_of_Cannabinoids_in_COVID-19_Progression_and_Treatment)[Interaction Points for Cannabinoids in COVID-19 Progression](#Interaction_Points_for_Cannabinoids_in_COVID-19_Progression)
- [Cannabinoids and Immune Response](#Cannabinoids_and_Immune_Response)
- [Inflammation and Cytokine Storm](#Inflammation_and_Cytokine_Storm)
- [Symptom Management](#Symptom_Management)
- [🌐 Explore Related CED Clinical Summary Hubs & Research](#_Explore_Related_CED_Clinical_Summary_Hubs_Research)

#### 🔍 CED Perspective Lens: Cannabis and COVID-19

Dr. Benjamin Caplan, MD

**🌱 Clinical Focus:**
 Detailed evidence review on cannabis and covid-19, physiology, and therapeutic applications.
 

**💡 Clinical Guidance:**
 Dosing considerations, bioavailability pathways, and evidence-grounded risk management.
 

**📖 Research & Data:**
 Preserving authoritative charts, diagrams, clinical tables, and scientific reference data.
 

### Understanding the Potential Role of Cannabinoids in COVID-19 Progression and Treatment

The diagram aims to illustrate a multifaceted perspective on how cannabinoids could interact with various stages and components of COVID-19 infection and symptomatology. It explores potential interaction points for cannabinoids, covering aspects like immune response modulation, inflammation control, cytokine storm management, and symptom relief. Below, the text further elucidates these critical points.

#### Interaction Points for Cannabinoids in COVID-19 Progression

- **Extracellular Mechanisms**Cannabinoids, particularly cannabidiol (CBD), have been observed to interfere with the entry of viruses into host cells. CBD is thought to act on the cell membrane, altering its flexibility and thus reducing the virus’s ability to fuse with and enter the host cell [Russo, E. B. (2016). Cannabinoids in the Pathophysiology of Skin Inflammation. *Molecules*, 21(8), 1063.].

- **Intracellular Mechanisms**Within the cell, cannabinoids like tetrahydrocannabinol (THC) and CBD have been shown to modulate intracellular pathways. They can downregulate the expression of certain cytokines and promote anti-inflammatory responses through interaction with nuclear receptors [Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. *Future medicinal chemistry*, 1(7), 1333-1349].

- **P-Par-Gamma Mechanisms**Peroxisome proliferator-activated receptor gamma (P-Par-Gamma) serves as another target for cannabinoids. Cannabinoids are known to activate this receptor, resulting in anti-inflammatory actions, which could potentially be beneficial in managing cytokine storms [O’Sullivan, S. E. (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. *British Journal of Pharmacology*, 152(5), 576-582].

- **ACE-Receptor Interactions**The ACE2 receptor plays a significant role in SARS-CoV-2’s ability to infect human cells. Some studies have hypothesized that cannabinoids might modulate ACE2 receptor expression, although further research is needed in this area [Chen, B., & Zang, W. (2020). Potential Implications of Cannabinoids in the Management of ACE2 Expression in COVID-19. *Journal of Medical Virology*, 92(11), 2802-2803].

#### Cannabinoids and Immune Response

Cannabinoids like [CBD](https://cedclinic.com/topic-cannabinoids/) and THC have immunomodulatory properties. While they can suppress an overactive immune response, potentially preventing or mitigating a cytokine storm, they can also enhance immune response under certain conditions [Klein, T. W. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nature Reviews Immunology*, 5(5), 400-411].

#### Inflammation and Cytokine Storm

Overreaction of the immune system, manifesting as a cytokine storm, is one of the severe complications of COVID-19. Cannabinoids are known for their anti-inflammatory properties and could serve as agents to reduce such overreactions [Chiurchiù, V., Leuti, A., & Maccarrone, M. (2018). Bioactive lipids and chronic inflammation: Managing the fire within. *Frontiers in Immunology*, 9, 38].

#### Symptom Management

While not a cure for COVID-19, cannabinoids may offer symptomatic relief for patients dealing with pain, anxiety, or [sleep](https://cedclinic.com/topic-cannabis-sleep-insomnia/) disturbances during their illness [Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Schmidlkofer, S. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA*, 313(24), 2456-2473.].

📗 Note: The diagram was your warm-up lap; the book is your marathon. [Cross the finish line here 📗](https://amzn.to/4a35lhE)

[https://amzn.to/4a35lhE](https://amzn.to/4a35lhE)[Unlock the world of medical cannabis with The Doctor-Approved Cannabis Handbook.](https://amzn.to/4a35lhE)

[← Back to Medical Applications Summary Hub](https://cedclinic.com/topic-medical-applications/)

#### 🌐 Explore Related CED Clinical Summary Hubs & Research

[😴 Sleep & Insomnia Hub →](https://cedclinic.com/topic-cannabis-sleep-insomnia/)
[🧬 Bioavailability Hub →](https://cedclinic.com/topic-bioavailability-pathway-decisions/)
[💊 Clinical Dosing Hub →](https://cedclinic.com/topic-dosage/)
[⚡ Pain Control Hub →](https://cedclinic.com/topic-pain-control/)

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).